Why Fortress Biotech Stock Is Sinking Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
AACR Meeting Presentations
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday)
Blueprint Medicines Corporation (NASDAQ: BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday)
Mirati Therapeutics, Inc. (NASDAQ: MRTX) and
BeiGene, Ltd. (NASDAQ: BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati s sitravatinib plus BeiGene s tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday)
Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday)
30 Stocks Moving in Friday s Pre-Market Session Benzinga 3 hrs ago
Gainers
Celcuity Inc. (NASDAQ: CELC) rose 32.3% to $19.00 in pre-market trading after the company reported a worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib. The company also reported preliminary data from Phase 1b Trial of gedatolisib plus ibrance and endocrine therapy for patients with ER+/HER2- metastatic breast cancer.
Gulf Resources, Inc. (NASDAQ: GURE) rose 29.5% to $6.02 in pre-market trading after the company reported a narrower loss for the fourth quarter.
TherapeuticsMD, Inc. (NASDAQ: TXMD) rose 19% to $1.57 in pre-market trading after the company, and Theramex, announced the approval of BIJUVE capsules indicated for hormone replacement therapy in the U.K. and under the trade name BIJUVA in Belgium.
Actinium Pharmaceuticals Inc (NYSE:ATNM), Bristol-Myers Squibb Company (NYSE:BMY) - Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Our six dermatology products are marketed by our partner company, Journey Medical Corporation (“Journey”).
Our products generated net revenues of $44.5 million for full-year 2020, compared to full-year 2019 net revenues of $34.9 million, representing growth of 28%. Our products generated $13.7 million in revenues in the fourth quarter of 2020, compared to $11.1 million in the fourth quarter of 2019, representing growth of 23%. While we generated revenue growth year-over-year in 2020, sales of our products were impacted by the COVID-19 pandemic, which caused a temporary supply shortage and impacted the ability of our sales force to make in person calls, due to states slowly re-opening.
We in-licensed and recently launched our sixth prescription dermatology product.